PX1 Research has introduced a new line of US-manufactured sublingual peptide strips designed for needle-free research applications. The product range includes formulations of Retatrutide, Tirzepatide, and BPC-157, marking a move away from traditional injectable formats toward non-invasive oral delivery. This development is significant for researchers who require alternatives to needle-based administration in their study designs.
The strips are produced under current Good Manufacturing Practice (cGMP) protocols within the United States, ensuring a high standard of quality control throughout the manufacturing process. Each batch undergoes High-Performance Liquid Chromatography (HPLC) purity verification, with results confirming 99% or greater purity across all formulations. A Certificate of Analysis accompanies every product, providing documented evidence of batch composition—a critical requirement for institutional research that demands supply chain transparency.
Among the available formulations, dissolving Retatrutide strips have attracted attention due to the compound's role in metabolic and weight regulation research. Additionally, Tirzepatide and BPC-157 are included in the lineup, addressing research areas such as glucose regulation and tissue repair. The sublingual format allows the strip to dissolve under the tongue, facilitating absorption without needles or syringes. This delivery method is particularly beneficial for research environments where non-invasive administration is a protocol requirement or where ethical considerations favor minimizing participant discomfort.
The launch of these strips addresses a logistical gap that injectable peptides cannot fill. For academic and institutional researchers, the ability to administer compounds sublingually can simplify study procedures and reduce potential complications associated with needle use. The full product line is accessible through PX1 Research, with specific information on the dissolving Retatrutide strips available on the product page.
PX1 Research has positioned these sublingual peptide strips specifically for academic and institutional research contexts. They are not intended for clinical, therapeutic, or human consumption. Instead, the product meets the demand from researchers who require compounds in a format compatible with non-invasive study designs, where traditional needle-based administration would introduce procedural variables or ethical concerns. The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds like Retatrutide and Tirzepatide signals that the line serves a range of research disciplines, with each formulation adapted to the stability and absorption characteristics of its respective compound.
